Pharmaceuticals, Biotechnology and Life Sciences
Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to…
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results…
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse…
Basel, 9 December 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for…
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology…
Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23…
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH,…
Company to host conference call on Wednesday, December 11, 2024 at 7am ETCAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) —…
January 13-16, 2025, San Francisco, CAIRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics…
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study…